Harrow (HROW) Competitors $43.54 +1.10 (+2.59%) (As of 02:21 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends HROW vs. AVEO, KIN, LFVN, BPMC, NUVL, VKTX, CORT, CYTK, IONS, and TGTXShould you be buying Harrow stock or one of its competitors? The main competitors of Harrow include AVEO Pharmaceuticals (AVEO), Kindred Biosciences (KIN), LifeVantage (LFVN), Blueprint Medicines (BPMC), Nuvalent (NUVL), Viking Therapeutics (VKTX), Corcept Therapeutics (CORT), Cytokinetics (CYTK), Ionis Pharmaceuticals (IONS), and TG Therapeutics (TGTX). These companies are all part of the "medical" sector. Harrow vs. AVEO Pharmaceuticals Kindred Biosciences LifeVantage Blueprint Medicines Nuvalent Viking Therapeutics Corcept Therapeutics Cytokinetics Ionis Pharmaceuticals TG Therapeutics Harrow (NASDAQ:HROW) and AVEO Pharmaceuticals (NASDAQ:AVEO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, community ranking, institutional ownership, valuation, dividends and profitability. Do analysts rate HROW or AVEO? Harrow presently has a consensus target price of $56.67, indicating a potential upside of 30.15%. Given Harrow's stronger consensus rating and higher possible upside, research analysts plainly believe Harrow is more favorable than AVEO Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harrow 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00AVEO Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor HROW or AVEO? AVEO Pharmaceuticals received 399 more outperform votes than Harrow when rated by MarketBeat users. Likewise, 70.68% of users gave AVEO Pharmaceuticals an outperform vote while only 58.28% of users gave Harrow an outperform vote. CompanyUnderperformOutperformHarrowOutperform Votes8858.28% Underperform Votes6341.72% AVEO PharmaceuticalsOutperform Votes48770.68% Underperform Votes20229.32% Which has more risk & volatility, HROW or AVEO? Harrow has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, AVEO Pharmaceuticals has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500. Does the media prefer HROW or AVEO? In the previous week, Harrow had 13 more articles in the media than AVEO Pharmaceuticals. MarketBeat recorded 13 mentions for Harrow and 0 mentions for AVEO Pharmaceuticals. Harrow's average media sentiment score of 0.63 beat AVEO Pharmaceuticals' score of 0.25 indicating that Harrow is being referred to more favorably in the media. Company Overall Sentiment Harrow Positive AVEO Pharmaceuticals Neutral Is HROW or AVEO more profitable? Harrow has a net margin of -19.75% compared to AVEO Pharmaceuticals' net margin of -30.79%. Harrow's return on equity of -45.57% beat AVEO Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Harrow-19.75% -45.57% -8.87% AVEO Pharmaceuticals -30.79%-81.66%-28.83% Which has preferable valuation and earnings, HROW or AVEO? Harrow has higher revenue and earnings than AVEO Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than AVEO Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarrow$130.19M11.91-$24.41M-$0.94-46.32AVEO Pharmaceuticals$42.29M12.33-$53.34M-$0.84-17.86 Do institutionals & insiders have more ownership in HROW or AVEO? 72.8% of Harrow shares are owned by institutional investors. Comparatively, 50.0% of AVEO Pharmaceuticals shares are owned by institutional investors. 13.7% of Harrow shares are owned by insiders. Comparatively, 3.3% of AVEO Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryHarrow beats AVEO Pharmaceuticals on 12 of the 18 factors compared between the two stocks. Ad Insiders Exposed917 Trades… Zero Losses?As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”Go here to see how you can start accessing these opportunities today Get Harrow News Delivered to You Automatically Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HROW vs. The Competition Export to ExcelMetricHarrowPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.55B$6.53B$5.10B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E Ratio-46.325.5095.1214.22Price / Sales11.91375.021,217.3088.42Price / CashN/A52.5939.4936.27Price / Book26.8810.276.976.37Net Income-$24.41M$153.22M$118.73M$225.56M7 Day Performance1.59%-1.19%-1.22%-0.02%1 Month Performance-22.83%-6.71%-3.07%2.04%1 Year Performance372.23%32.39%32.52%28.00% Harrow Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HROWHarrow3.7656 of 5 stars$43.54+2.6%$56.67+30.1%+348.6%$1.55B$130.19M-46.32182AVEOAVEO PharmaceuticalsN/A$15.00flatN/A+0.0%$521.45M$42.29M-17.86114KINKindred Biosciences0.8575 of 5 stars$9.25flatN/A+0.0%$420.52M$42.16M-16.8263Analyst ForecastLFVNLifeVantage2.948 of 5 stars$12.96+0.2%N/A+121.0%$162.26M$200.16M40.41260BPMCBlueprint Medicines2.7179 of 5 stars$97.09+2.4%$122.11+25.8%+43.9%$6.17B$249.38M0.00640Analyst ForecastAnalyst RevisionNUVLNuvalent2.1908 of 5 stars$93.15+2.2%$112.60+20.9%+51.1%$6.04BN/A0.0040VKTXViking Therapeutics4.7807 of 5 stars$53.22+3.3%$109.80+106.3%+337.8%$5.93BN/A-55.5620Analyst ForecastCORTCorcept Therapeutics4.7045 of 5 stars$56.34+0.4%$65.25+15.8%+116.2%$5.90B$482.38M44.52300Positive NewsCYTKCytokinetics4.0477 of 5 stars$48.38-3.0%$83.93+73.5%+54.3%$5.71B$7.53M-9.27250Analyst ForecastInsider TradeOptions VolumeNews CoverageIONSIonis Pharmaceuticals4.2328 of 5 stars$34.53-2.5%$60.65+75.6%-28.7%$5.45B$788M-14.43800TGTXTG Therapeutics4.2078 of 5 stars$34.24+9.9%$37.67+10.0%+143.0%$5.33B$233.66M-351.26290Positive News Related Companies and Tools Related Companies AVEO Pharmaceuticals Alternatives Kindred Biosciences Alternatives LifeVantage Alternatives Blueprint Medicines Alternatives Nuvalent Alternatives Viking Therapeutics Alternatives Corcept Therapeutics Alternatives Cytokinetics Alternatives Ionis Pharmaceuticals Alternatives TG Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HROW) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
